News for Formycon AG (0W4N.L)

EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon and Fresenius Kabi announce FDA Approval of Interchangeability f...

Revenue: Decreased from EUR17.7 million to EUR5.3 million, as anticipated due to changes in revenue structure.Adjusted EBITDA: EUR11.8 million, reflecting redu

May 12, 2025 / 01:00PM GMTStefan Glombitza - Formycon AG - Chief Executive Officer, Member of the Executive Board Good afternoon, good morning, and also from ou

Revenue: Reduced by approximately 10% in 2024, slightly less than anticipated.EBITDA: Influenced positively by one-off product sales and early milestone paymen

Mar 27, 2025 / 02:00PM GMTStefan Glombitza - Formycon AG - Chief Executive Officer, Member of the Executive Board Yeah, thank you for your introduction with Ern

Germany stocks mixed at close of trade; DAX up 0.24%

Teva Pharmaceutical collaborates with Klinge Biopharma and Formycon AG to commercialize Formycon's biosimilar candidate to Eylea in Europe.

**media[513023]**

Teva Pharmaceutical Industries Ltd (TEVA) announced on January 13, 2025, a strategic collaboration with Klinge Biopharma GmbH and Formycon AG for the semi-exclu

Revenue: Decrease compared to 2023, expected and within range.EBITDA: Decrease to minus EUR17.7 million, expected due to reduced revenues and increased R&D and

Nov 28, 2024 / 02:00PM GMTStefan Glombitza - Formycon AG - Chief Executive Officer, Member of the Executive Board Thank you very much for the kind introduction.

EQS-News: Formycon AG / Key word(s): 9 Month figures/Conference Formycon invites to earnings call on the nine-month results ...

EQS-News: Formycon AG / Key word(s): Statement/Regulatory Admission Formycon receives positive CHMP opinion for FYB203 (afli...

EQS-News: Formycon AG / Key word(s): Regulatory Admission/IPO Formycon applies for admission to the Prime Standard of the Fr...

Formycon announces positive FYB206 biosimilar study

FYB201 Royalties: EUR3.8 million, tripling from EUR1.1 million in H1 2023.FYB202 Deferred Milestones: EUR11.3 million, down from EUR23.7 million in H1 2023.Dev

Aug 13, 2024 / 01:00PM GMTStefan Glombitza - Formycon AG - Chief Executive Officer, Member of the Executive Board Thank you very much and warm welcome from my s

Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar Otulfi™* (ustekinumab-aauz)

EQS-News: Formycon AG / Key word: AGM/EGM/Personnel Formycon invites to the Annual General Meeting on June 12, 2024 in Munich 07.05.2024 / 11:00 CET/CEST The issuer...